Scrub Typhus Antibiotic Resistance Trial

Scrub Typhus Clinical Trial

— START  

Official title:

The Scrub Typhus Antibiotic Resistance Trial (START) Comparing Doxycycline and Azithromycin Treatment Modalities in Areas of Reported Antimicrobial Resistance for Scrub Typhus

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03083197
• Other study ID #: START
• Status: Recruiting
• Phase: Phase 4
• Start date: October 15, 2017
• Est. completion date: October 2024

Study information

• Verified date: March 2022
• Source: University of Oxford
• Contact: Assoc. Prof. Daniel Paris
• Phone: +6622036373
• Email: parigi[@]tropmedres.ac
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study type: Randomized Control Treatment Trial

Study population: Male and female patients with ≥15 years of age and acute scrub typhus

Duration: 2 years

Study Design: Prospective, open-label, randomized-controlled treatment trial in patients ≥15 years old admitted to hospital with acute scrub typhus. Randomization into 3 oral treatment arms (each n=59 patients, total n=177): i) 7 days of doxycycline, ii) 3 days of doxycycline, and iii) 3 days of azithromycin

Primary Objective: To evaluate the clinical and microbiological responses in scrub typhus patients to three oral treatment regimens: 7 days of doxycycline, 3 days of doxycycline, and 3 days of azithromycin

Secondary Objectives:

1. To perform pharmacokinetic/pharmacodynamics (PK/PD) characterization of the therapeutic responses for doxycycline and azithromycin, incl. serial bacterial load measurements.

2. To define clinical, bacterial, pathophysiological and pharmacological factors associated with disease severity, fever-clearance times (FCT), treatment failures and relapse/re-infection.

3. To determine the minimum inhibitory concentrations (MIC) of clinical Orientia tsutsugamushi isolates to doxycycline, azithromycin and chloramphenicol, using in vitro growth-inhibition assays

4. To genotype all clinical isolates using whole genome sequencing for comparative genomics.

5. To dissect the natural immune response in scrub typhus, using antigen-specific cellular immune and antibody studies, and cytokine profiling

Description:

The funder is USAMRMC - MIDRP and Grant No. DHP-Award D6.7_15_C2_I_15_J9_1317

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 177
• Est. completion date: October 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

• Age = 15 years old

• Hospitalization with acute undifferentiated fever (temperature > 37.5°C, tympanic) =14 days or patients admitted to hospital with a history of fever = 14 days who subsequently develop fever within 24 hours of admission

• Clinically suspected scrub typhus: defined as acute undifferentiated fever with no clear focus of infection and negative malaria blood smear and/or negative malaria RDT. Patients may have one, none, or a combination of other clinical findings such as eschar, rash, lymphadenopathy, headache, myalgia, cough, nausea and abdominal discomfort.

• A positive scrub typhus RDT (Scrub Typhus IgM RDT, InBios International, Seattle, WA, USA) and/or positive PCR-based detection of O. tsutsugamushi DNA from the admission blood sample

• Written informed consent and/or, written informed assent as required

• Able to take oral medication

Exclusion Criteria:

• Known hypersensitivity to tetracycline, doxycycline or azithromycin

• Administration of doxycycline, azithromycin, chloramphenicol, rifampicin, or tetracycline during the preceding 7 days

• Pregnancy or breast-feeding

• Patients with myasthenia gravis or systemic lupus erythematosus

• Patients with an established infection (diagnostic test required) e.g. acute malaria, dengue, leptospirosis, typhoid, Japanese encephalitis etc.

• Current TB or TB treatment in = 6 months (contain active antibiotics against Orientia spp.)

• Current HAART use for HIV, long term use of immunosuppressants (e.g. steroids, chemotherapy, TNF-inhibitors and related agents)

• Patients with severe disease whom the clinical team feel their condition necessitates the need for additional scrub typhus treatment beyond the allocated antibiotic treatment assigned at randomization (e.g. IV chloramphenicol and/or PO/NG rifampicin)

Related Conditions & MeSH terms

• Scrub Typhus

Intervention

Drug:
• Doxycycline 7 days
loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
• Doxycycline 3 days
loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
• Azithromycin 3 days
loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3

Locations

Country	Name	City	State
Thailand	Chiangrai Prachanukroh Hospital	Chiang Rai
Thailand	Shoklo-Malaria Research Unit (SMRU)	Mae Sot	Tak

Sponsors (3)

Lead Sponsor	Collaborator
University of Oxford	Chiangrai Prachanukroh Hospital, Shoklo Malaria Research Unit

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fever clearance time (FCT)	Based on the time from first dose of antibiotic treatment to when the tympanic temperature first falls =37.5°C and remains =37.5°C for at least 24 hours, outside of the influence of paracetamol.	at least 24 hours
Secondary	Resolution of bacteraemia in relation to Drug plasma level		8 Weeks
Secondary	Occurrence of severe disease or treatment failure/relapse		8 Weeks
Secondary	Presence of in vitro antimicrobial resistance	(Minimum inhibitory concentrations (MIC) over susceptibility cut off)	8 Weeks
Secondary	Genotyping of clinical Orientia tsutsugamushi isolates (56kDa gene +/- whole genome sequencing)	Genotyping of clinical OT isolates will be performed on patient samples that are PCR positive (approximately 50-60%) and/or culture positive (approximately 30%). Extracted DNA will be sent for 56kDa gene sequencing +/- whole genome sequencing, revealing the clinically important strains and allowing for comparative analysis with disease severity and patient outcomes.	2 years
Secondary	Antigen-specific positive cellular and humoral immune responses		8 Weeks